a4546m
FORM 6-K
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Report
of Foreign Issuer
Pursuant
to Rule 13a-16 or 15d-16 of
the
Securities Exchange Act of 1934
For the
month of May 2020
Commission
File Number: 001-11960
AstraZeneca PLC
1
Francis Crick Avenue
Cambridge
Biomedical Campus
Cambridge
CB2 0AA
United
Kingdom
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F X Form 40-F __
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1):
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ______
Indicate
by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information
to the Commission pursuant to Rule 12g3-2(b) under the Securities
Exchange Act of 1934.
Yes __
No X
If
“Yes” is marked, indicate below the file number
assigned to the Registrant in connection with Rule 12g3-2(b):
82-_____________
AstraZeneca PLC
INDEX
TO EXHIBITS
1.
AstraZeneca recovery of global rights to brazikumab (MEDI2070) from Allergan
completed
11 May 2020 07:00 BST
AstraZeneca recovery of global rights
to brazikumab (MEDI2070) from Allergan completed
AstraZeneca has completed a previously
communicated agreement to recover the global
rights to brazikumab (formerly
MEDI2070), a monoclonal antibody targeting IL23,
from Allergan. AstraZeneca and Allergan have terminated
their previous license
agreement and all rights
to brazikumab have therefore now returned to
AstraZeneca.
Financial considerations
Under the termination agreement, Allergan will fund up to an agreed
amount, estimated to be the total costs expected to be incurred by
AstraZeneca until completion of the development of brazikumab for
Crohn's disease (CD) and ulcerative colitis (UC), including the
development of a companion diagnostic.
Pursuant to the 2012
collaboration between
Amgen and AstraZeneca to jointly develop and commercialise a
clinical-stage inflammation portfolio, including brazikumab, Amgen
is entitled to receive a high single-digit to low double-digit
royalty on sales of brazikumab if approved and launched. This
includes the original inventor royalty. Other than this,
AstraZeneca will own all rights and benefits arising from the
medicine with no other payments due to Amgen or
Allergan.
Brazikumab
Brazikumab is a monoclonal antibody that binds to the IL23 receptor
and is in development for CD and UC with a companion biomarker.
Brazikumab selectively blocks the IL23 immune signal, preventing
intestinal inflammation. In Phase II trials, brazikumab
demonstrated a clinical effect at week eight in tumour necrosis
factor-resistant CD patients.1 The
Phase IIb/III INTREPID programme is underway to assess brazikumab
compared to placebo or adalimumab in CD. The Phase II EXPEDITION
trial is underway to assess brazikumab compared to placebo or
vedolizumab in UC. With current
biologic medicines, 40% to 55% of patients have no response to
therapy, and 65% to 80% of patients do not experience a full
remission.2
AstraZeneca
AstraZeneca (LSE/STO/NYSE: AZN) is a global, science-led
biopharmaceutical company that focuses on the discovery,
development and commercialisation of prescription medicines,
primarily for the treatment of diseases in three therapy areas -
Oncology, Cardiovascular, Renal & Metabolism, and Respiratory
& Immunology. Based in Cambridge, UK, AstraZeneca operates in
over 100 countries and its innovative medicines are used by
millions of patients worldwide. Please
visit astrazeneca.com and
follow the Company on Twitter @AstraZeneca.
Contacts
For details on how to contact the Investor Relations Team, please
click here.
For Media contacts, click here.
References
1. Sands BE, Chen J, Feagan BG et al. Efficacy and Safety of MEDI2070, an Antibody
Against Interleukin 23, in Patients With Moderate to Severe Crohn's
Disease: A Phase 2a Study. Gastroenterology.
2017;153:77-86.
2. Sandborn W. J. (2016).
The Present and Future of Inflammatory Bowel Disease
Treatment. Gastroenterology
& hepatology, 12(7),
438-441.
Adrian Kemp
Company Secretary
AstraZeneca PLC
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
Date:
11 May
2020
|
By: /s/
Adrian Kemp
|
|
Name:
Adrian Kemp
|
|
Title:
Company Secretary
|